Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $35.09 USD
Change Today +0.56 / 1.62%
Volume 19.4M
PFE On Other Exchanges
Symbol
Exchange
Xetra
Mexico
SIX Swiss Ex
Sao Paulo
Bogota
As of 3:51 PM 03/30/15 All times are local (Market data is delayed by at least 15 minutes).

pfizer inc (PFE) Key Developments

Pfizer Inc. Announces Oral Tofacitinib Meets Primary Endpoints in Pivotal Phase 3 Psoriasis Trials

Pfizer Inc. announced the presentation of detailed pooled results from two pivotal Phase 3 studies from the Oral treatment P soriasis Trials (OPT) program at the 73rd American Academy of Dermatology (AAD) Annual Meeting. These results, evaluating the efficacy and safety of tofacitinib citrate for the treatment of adults with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, have been selected for oral presentation during the Pearls from the Posters New and Noteworthy Research Finds. Additionally, an integrated analysis of safety data from the OPT global clinical development program for tofacitinib was presented during the Late-Breaking Research in Dermatology Forums. The detailed, pooled analysis of 16 week data from the OPT Pivotal #1 and OPT Pivotal #2 studies showed that tofacitinib 10 mg and 5 mg tablets twice daily met the co-primary efficacy endpoints of superiority over placebo at 16 weeks in the proportion of patients achieving a Physicians Global Assessment (PGA) response of clear or almost clear, and the proportion of patients achieving at least a 75% reduction in Psoriasis Area and Severity Index (PASI75), two commonly used measures of efficacy in psoriasis. Both the tofacitinib 10 mg and 5 mg twice-daily doses showed statistically significant superiority over placebo for key secondary efficacy endpoints presented at AAD, including proportion of patients achieving ?90% reduction in PASI (PASI90) relative to baseline at Week 16% change from baseline in Body Surface Area (BSA) at Week 16, change from baseline in Dermatology Life Quality Index (DLQI) at Week 16, and percentage change from baseline in Nail Psoriasis Severity Index (NAPSI) at Week 16 in patients with nail psoriasis.

Pfizer Inc. Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015

Pfizer Inc. Presents at 2015 Deutsche Bank Pharma OneonOne Day, Mar-26-2015 . Venue: JW Marriott Denver at Cherry Creek, 150 Clayton Lane, Denver, CO 80206, United States.

Pfizer & Eli Lilly to Resume Tanezumab Phase 3 Program

Pfizer Inc. (PFE) and Eli Lilly and Company (LLY) announced that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200 million upfront payment from Lilly in accordance with the collaboration agreement. A partial clinical hold has been in place for tanezumab and all other anti-nerve growth factor antibodies since December 2012 due to adverse changes in the sympathetic nervous system of mature animals. U.S. FDA decided to lift the partial clinical hold after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab. The data were submitted to the FDA in February 2015.

Pfizer Inc. Reports Top-Line Results from Phase 4 Study Evaluating LYRICA Capsules CV as Treatment for Adolescents with Fibromyalgia

Pfizer Inc. announced top-line results of a double-blind Phase 4 study evaluating the safety and efficacy of Lyrica (pregabalin) Capsules CV in adolescents (ages 12-17 years) with fibromyalgia. The primary endpoint of the study was not achieved as there was not a statistically significant difference between pregabalin and placebo in mean pain score. The treatment difference was 0.66 points, which reflects an improvement of 1.60 points from baseline for pregabalin-treated patients and 0.94 points for placebo (p=0.121). This study was conducted to fulfill a post-marketing commitment required by the U.S. Food and Drug Administration when Lyrica was approved for the management of fibromyalgia. The safety and efficacy of pregabalin in pediatric patients have not been established. A total of 107 adolescent patients were enrolled in this Phase 4, 15-week double-blind, randomized, placebo-controlled study from multiple centers across the U.S., Europe and Asia. This study is the first large pharmacological treatment study to be completed in this study population. Study medication was administered twice daily. Dosing started at 75 mg/day and was optimized over a 3 week period, based on tolerability and response, to a dose of 75 mg/day, 150 mg/day, 300 mg/day or 450 mg/day, with the optimized dose maintained for the next 12 weeks. The safety profile observed in this study is consistent with the known profile for Lyrica in prior fibromyalgia studies in adults, with the exception of mild nausea, which occurred at a higher rate in pregabalin-treated patients. The most common adverse events in this study in pregabalin treated patients were dizziness, nausea, headache, increased weight and fatigue. Full results from the study are expected to be submitted for publication when analyses are complete.

Pfizer Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 11:30 AM

Pfizer Inc. Presents at 12th Annual BIO Asia International Conference, Mar-25-2015 11:30 AM. Venue: Grand Hyatt Hotel, Tokyo, Japan.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PFE:US $35.09 USD +0.56

PFE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Merck & Co Inc $58.38 USD +0.63
Nestle SA SFr.74.25 CHF +1.15
Novartis AG SFr.97.85 CHF +1.65
Roche Holding AG SFr.265.00 CHF +1.80
Procter & Gamble Co/The $82.78 USD +0.47
View Industry Companies
 

Industry Analysis

PFE

Industry Average

Valuation PFE Industry Range
Price/Earnings 24.4x
Price/Sales 4.4x
Price/Book 3.0x
Price/Cash Flow 16.1x
TEV/Sales 2.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PFIZER INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.